Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 138
Notice: Undefined index: new_doi_fields in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 174
Notice: Trying to access array offset on value of type null in /home/daan/projects/medicalconferences_dev/wp-content/themes/writers-blogily-child/functions.php on line 175
TOSCA is 1 of the 6 randomised, phase 3 clinical trials of the IDEA consortium, demonstrating non-inferiority of 3 months adjuvant chemotherapy as compared with 6 months chemotherapy in patients with stage III colon cancer [1]. However, a reduced benefit of adjuvant chemotherapy for patients over the age of 70 years is suggested.
Therefore, a subgroup analysis of TOSCA was performed [2]. Primary endpoint of this subgroup analysis was relapse-free interval (RFI), defined as time from randomisation to relapse or last disease evaluation. In TOSCA, 2,360 patients with stage III disease were enrolled: 1,667 aged <70 (‘younger patients’) and 693 aged ≥70 (‘elderly patients’). The elderly patients had an ECOG performance status more often equal to 1 compared with the younger patients (10% vs 3%), more T3/T4 tumours (91% vs 84%), and more tumours located on the right (49% vs 36%). More elderly patients had dose reductions (47% vs 41%) and prematurely interrupted the treatment (26% vs 19%).
In elderly patients, a higher proportion of recurrences was observed (24% vs 20%; P=0.033). However, the multivariable analysis of the RFI, corrected for sex, ECOG performance status, tumour site, stage, and grade, treatment, treatment duration, and dose reduction, did not indicate a statistically significant effect of age (HR 1.19; P=0.082). As such, different prognostic factors and possibly a reduced compliance may account for the observed difference in benefit of adjuvant chemotherapy between elderly and younger patients.
- Grothey A, N Engl J Med 2018;378:1177-1188.
- Rosati G, et al. Oxaliplatin plus fluoropyrimidines as adjuvant therapy for colon cancer in elderly patients: A subgroup analysis from TOSCA trial. ESMO 2020 Virtual Meeting, abstract 399O.
Posted on
Previous Article
« Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? Next Article
Surveillance after curative treatment for CRC »
« Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer? Next Article
Surveillance after curative treatment for CRC »
Table of Contents: ESMO 2020
Featured articles
COVID-19 and Cancer
Breast Cancer
Gastrointestinal Cancers
Lung Cancer
Melanoma
Genitourinary Cancers
Bladder cancer risk and early detection
Gynaecological Cancers
Basic Science
Related Articles

November 25, 2020
Second-line sacituzumab govitecan improves survival in metastatic TNBC
November 25, 2020
Immuno-combination therapy in metastatic melanoma
November 25, 2020
First-line immune-combination therapies in mUC
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy